Wuhan Easy Diagnosis Biomedicine News

Mingde Biotech (002932): Continued high performance growth, scale effects highlight boosting profitability

方正證券Aug 25, 2022 00:00

Mingde Biology (002932): COVID-19 nucleic acid test+antigen test two-wheel drive performance achieved explosive growth

方正證券Apr 26, 2022 00:00

Mingde Biology (002932): The large-scale effect of normalization of nucleic acid testing, increased profitability, and Q1 performance exceeded expectations

方正證券Apr 13, 2022 00:00

Mindoku Biotech (002932) In-depth Report: Emerging Growth Forces in the POCT Field

財通證券Jul 23, 2018 00:00

Mingde Biological (002932) IPO Investment value Analysis: dedicated POCT leaders are expected to continue to benefit from the rapid growth of the industry

中泰證券Jul 9, 2018 00:00